{"title": "The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells", "doi": "10.1101/2020.01.31.929042", "citation_id": "2020.01.31.929042v1", "date": "2020-01-31", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.01.31.929042", "abstract": "<h3>Abstract</h3>\n<p>The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviruses use their spike proteins to select and enter target cells and insights into nCoV-2019 spike (S)-driven entry might facilitate assessment of pandemic potential and reveal therapeutic targets. Here, we demonstrate that 2019-nCoV-S uses the SARS-coronavirus receptor, ACE2, for entry and the cellular protease TMPRSS2 for 2019-nCoV-S priming. A TMPRSS2 inhibitor blocked entry and might constitute a treatment option. Finally, we show that the serum form a convalescent SARS patient neutralized 2019-nCoV-S-driven entry. Our results reveal important commonalities between 2019-nCoV and SARS-coronavirus infection, which might translate into similar transmissibility and disease pathogenesis. Moreover, they identify a target for antiviral intervention.</p><h3>One sentence summary</h3>\n<p>The novel 2019 coronavirus and the SARS-coronavirus share central biological properties which can guide risk assessment and intervention.</p>", "twitter_description": "The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviruses use their spike proteins to select and enter target cells and insights into nCoV-2019 spike (S)-driven entry might facilitate assessment of pandemic potential and reveal therapeutic targets. Here, we demonstrate that 2019-nCoV-S uses the SARS-coronavirus receptor, ACE2, for entry and the cellular protease TMPRSS2 for 2019-nCoV-S priming. A TMPRSS2 inhibitor blocked entry and might constitute a treatment option. Finally, we show that the serum form a convalescent SARS patient neutralized 2019-nCoV-S-driven entry. Our results reveal important commonalities between 2019-nCoV and SARS-coronavirus infection, which might translate into similar transmissibility and disease pathogenesis. Moreover, they identify a target for antiviral intervention.\n\nOne sentence summary The novel 2019 coronavirus and the SARS-coronavirus share central biological properties which can guide risk assessment and intervention.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/01/31/2020.01.31.929042.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.01.31.929042v1", "access_rights": "restricted", "authors": ["Markus Hoffmann", "Hannah Kleine-Weber", "Nadine Kr\u00fcger", "Marcel M\u00fcller", "Christian Drosten", "Stefan P\u00f6hlmann"]}